Catalyst Pharmaceuticals Inc
NASDAQ:CPRX

Watchlist Manager
Catalyst Pharmaceuticals Inc Logo
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Watchlist
Price: 24.46 USD 2.26% Market Closed
Market Cap: 3B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CPRX stock under the Base Case scenario is hidden USD. Compared to the current market price of 24.46 USD, Catalyst Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CPRX Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

6
P/S
P/S
Price to Sales
6
vs History
15
vs Industry
54
Median 3Y
5.1
Median 5Y
4.7
Industry
7
Forward
5.2
More Details
18
P/E
P/E
Price to Earnings
18
vs History
42
vs Industry
8
Median 3Y
19.4
Median 5Y
16.9
Industry
21.5
Forward
16.9
More Details
12.3
P/OCF
P/OCF
Price to OCF
12.3
vs History
34
vs Industry
12
Median 3Y
11.8
Median 5Y
11.5
Industry
20
More Details
12.4
P/FCFE
P/FCFE
Price to FCFE
12.4
vs History
34
vs Industry
11
Median 3Y
11.8
Median 5Y
11.7
Industry
25.4
More Details
4.1
P/B
P/B
Price to Book Value
4.1
vs History
31
vs Industry
23
Median 3Y
3.9
Median 5Y
3.8
Industry
2.4
More Details
5
EV/S
EV/S
Enterprise Value to Sales
5
vs History
15
vs Industry
49
Median 3Y
4.3
Median 5Y
3.8
Industry
7.3
Forward
4.3
More Details
5.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.8
vs History
15
vs Industry
51
Median 3Y
5
Median 5Y
4.3
Industry
9.3
More Details
10.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.5
vs History
46
vs Industry
11
Median 3Y
11.8
Median 5Y
9.8
Industry
4
Forward
14.7
More Details
12.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.5
vs History
36
vs Industry
9
Median 3Y
12.9
Median 5Y
10.7
Industry
3.8
Forward
10.8
More Details
10.2
EV/OCF
EV/OCF
Enterprise Value to OCF
10.2
vs History
34
vs Industry
13
Median 3Y
10.1
Median 5Y
9.6
Industry
4.9
More Details
10.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
10.2
vs History
36
vs Industry
10
Median 3Y
10.1
Median 5Y
9.6
Industry
3.3
More Details
7.7
EV/IC
EV/IC
Enterprise Value to IC
7.7
vs History
46
vs Industry
22
Median 3Y
6.4
Median 5Y
7.1
Industry
4.3
More Details

Multiples Across Competitors

CPRX Competitors Multiples
Catalyst Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
3B USD 6 18 10.5 12.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 416 774.3 -173 083.5 -210 178.5 -207 780.2
US
Abbvie Inc
NYSE:ABBV
362.2B USD 6.4 85.5 16.8 25.3
US
Amgen Inc
NASDAQ:AMGN
164.1B USD 4.9 40.1 16.2 28.8
US
Gilead Sciences Inc
NASDAQ:GILD
138.4B USD 4.8 288.3 11.3 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.2B USD 11.3 -231.9 25.4 26.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 934.5 -493.6 -537.6 -523.2
AU
CSL Ltd
ASX:CSL
121.6B AUD 5 27.8 17.1 21.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
68.6B USD 4.8 15.5 10 11.1
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -57.1 -61.5 -55.5
NL
argenx SE
XBRU:ARGX
32.5B EUR 16.2 42.5 313.1 -2 306.4
P/S Multiple
Revenue Growth P/S to Growth
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Average P/S: 3 310 798.8
6
12%
0.5
FR
Pharnext SCA
OTC:PNEXF
36 416 774.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.3
10%
1.1
US
E
Epizyme Inc
F:EPE
1 934.5
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.8
7%
0.7
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
NL
argenx SE
XBRU:ARGX
16.2
37%
0.4
P/E Multiple
Earnings Growth PEG
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Average P/E: 74
18
10%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 083.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
85.5
87%
1
US
Amgen Inc
NASDAQ:AMGN
40.1
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
288.3
187%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -231.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -493.6 N/A N/A
AU
CSL Ltd
ASX:CSL
27.8
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.5
12%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.1 N/A N/A
NL
argenx SE
XBRU:ARGX
42.5
26%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Average EV/EBITDA: 52.5
10.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 178.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.8
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.2
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -537.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.5 N/A N/A
NL
argenx SE
XBRU:ARGX
313.1
166%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Average EV/EBIT: 20
12.5
17%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -207 780.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.3
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.2 N/A N/A
AU
CSL Ltd
ASX:CSL
21.4
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.5 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 306.4 N/A N/A

See Also

Summary
CPRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
CPRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CPRX stock valuation using valuation multiples.
Wall Street Estimates
CPRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CPRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 243,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.